{"id":"W3029686450","doi":"10.1200/jco.2020.38.15_suppl.5566","title":"TALAPRO-1: Phase II study of talazoparib (TALA) in patients (pts) with DNA damage repair alterations (DDRm) and metastatic castration-resistant prostate cancer (mCRPC) – updated interim analysis (IA).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Pfizer","keywords":"Medicine; Internal medicine; Oncology; Prostate cancer; Docetaxel; Clinical endpoint; Taxane; Enzalutamide; Phases of clinical research; Urology; Cancer; Surgery; Chemotherapy; Clinical trial; Breast cancer; Androgen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001808404,0.001410475,0.001132807,0.0004552432,0.0003058101,0.001018129,0.0008735862,0.0009199269,0.006722391],"category_scores_gemma":[0.0009996602,0.0004811381,0.001203955,0.0003691616,0.0006108379,0.0008816671,0.0004697285,0.002533014,0.001335021],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008703155,"about_ca_system_score_gemma":0.001345079,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00100061,"about_ca_topic_score_gemma":0.003260248,"domain_scores_codex":[0.9996816,0.0001407219,0.00001433674,0.00005159748,0.00003931919,0.00007242224],"domain_scores_gemma":[0.9993761,0.00007108242,0.000117729,0.00003092936,0.0000462592,0.0003580104],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7520593,0.04675657,0.01235494,0.001805335,0.003021692,0.0004415098,0.0004322291,0.006004305,0.03793264,0.0009755623,0.0199654,0.1182505],"study_design_scores_gemma":[0.7109621,0.2577571,0.0153969,0.00009647464,0.001257809,0.0006025865,0.0001170744,0.002496615,0.003210107,0.0007071714,0.00734653,0.00004952922],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9743252,0.003576084,0.001218431,0.001509074,0.0002066681,0.005259359,0.006703358,0.0002767957,0.006924992],"genre_scores_gemma":[0.968024,0.002578947,0.002422928,0.002731904,0.0002308302,0.003945379,0.01263623,0.00008169687,0.007348156],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006722391,"threshold_uncertainty_score":0.02248865,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1325199531882151,"score_gpt":0.494144011813852,"score_spread":0.3616240586256369,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}